Does USTEKINUMAB Cause C-reactive protein abnormal? 1,450 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,450 reports of C-reactive protein abnormal have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 1.7% of all adverse event reports for USTEKINUMAB.
1,450
Reports of C-reactive protein abnormal with USTEKINUMAB
1.7%
of all USTEKINUMAB reports
904
Deaths
1,244
Hospitalizations
How Dangerous Is C-reactive protein abnormal From USTEKINUMAB?
Of the 1,450 reports, 904 (62.3%) resulted in death, 1,244 (85.8%) required hospitalization, and 1,015 (70.0%) were considered life-threatening.
Is C-reactive protein abnormal Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 1,450 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause C-reactive protein abnormal?
METHOTREXATE (3,734)
ADALIMUMAB (3,629)
ETANERCEPT (3,592)
ABATACEPT (3,402)
LEFLUNOMIDE (3,279)
TOCILIZUMAB (3,259)
HYDROXYCHLOROQUINE (3,245)
SULFASALAZINE (2,823)
INFLIXIMAB (2,676)
RITUXIMAB (2,608)
Which USTEKINUMAB Alternatives Have Lower C-reactive protein abnormal Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE